Central Nervous System (CNS) Stimulant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Central Nervous System (CNS) Stimulant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The central nervous system (CNS) stimulant drugs market is expected to register a CAGR of 5.5% over the forecast period.

Key Highlights

• The COVID-19 pandemic substantially impacted the central nervous system (CNS) stimulant drugs. With the outbreak of COVID-19, the central nervous system stimulant drugs market experienced a decrease in its growth. With the increasing number of COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affected the respiratory system, it was reported to have shown effects on central and peripheral systems.
• Supply chain disruption, government-imposed lockdowns, and trade bans in several countries significantly impacted the market of CNS stimulant drugs. The COVID-19 pandemic had three significant effects on the global market for major nervous system stimulant drugs: it directly affected the production and demand of central nervous system (CNS) stimulant drugs, it disrupted distribution channels, and it had a financial impact on firms and financial markets. However, during the pandemic, remote consultation emerged, which enabled doctors to assess ADHD patients.
• For instance, a European Child & Adolescent Psychiatry in February 2023 highlighted the potential of remote technologies to evaluate attention deficit hyperactivity disorder (ADHD) in children and adolescents. In the post-pandemic phase, COVID-19 cases decreased, and treatment for other diseases resumed. This has rebounded the growth pace of the central nervous system (CNS) Stimulant Drugs market as it was in the pre-pandemic phase. Thus, the COVID-19 outbreak impacted the market's growth in its preliminary stage. Moreover, the market is expected to grow at an average pace with the resumption of treating other diseases, including ADHD, sleeping disorders, and others.
• The significant factor attributing to this market's growth is CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder, which have witnessed a substantial rise in recent years. According to a study published in the American Thoracic Society in 2022, obstructive sleep apnea (OSA) has a global prevalence of over 22.6%. The expanding senior population significantly impacts the CNS stimulant drugs market. The aged individual has a high risk of developing central nervous system issues such as sleeping disorders, ADHD, and others, which require CNS stimulant drugs for their effective management. Over 20% of the elderly population have a state of sleep apnea and daytime sleepiness.
• For instance, according to Sleep Care Online, the shape of sleep apnea in elderly patients aggravates the pre-existing medical conditions common in older patients, including hypertension, cardiovascular issues, and diabetes. For instance, as per the data published by Vikaspedia in 2021, the proportion of the elderly population has been increasing over several years, and it increased to 10.1% in 2021, which is further anticipated to increase to 13.1% by 2031. Thus, the expanding geriatric population is anticipated to boost the demand for CNS stimulant drugs, which will boost the growth of the market in the coming years.
• Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period. However, numerous side effects of drugs are expected to hinder the market's growth during the forecast period.

Central Nervous System (CNS) Stimulant Drugs Market Trends

The Attention-Deficit Hyperactivity Disorder Segment is Expected to Witness Significant Growth Over the Forecast Period

• The attention-deficit hyperactivity disorder segment is expected to hold a significant market share in the central nervous system (CNS) stimulant drugs market over the forecast period. Factors such as the rising prevalence of attention-deficit hyperactivity disorder amongst children and adolescents and the easy availability of treatment drugs such as CNS stimulants will likely propel the segment growth over the forecast period.
• For instance, per the data published by the National Health Insurance Corporation of South Korea in March 2023, the number of individuals diagnosed with attention-deficit hyperactivity (ADHD) has increased in the past few years, and it reached 102,322 in 2021. Further, as per the Centers for Disease Control and Prevention (CDC), in 2021, the approximate number of children detected with attention-deficit/hyperactivity disorder was 6.1 million, with a prevalence rate of 9.4%.
• Additionally, as per the research study published in the Journal of Education and Health Promotion in 2021, Approximately 5% of kids worldwide suffer from ADHD. According to the same source, 5.29% in Northern America, 12.3% in Southern America, 8.9% in Africa, the Middle East 2.5%, 4.8% in Australia, and Asia account for a 4.2% prevalence of attention-deficit hyperactivity.
• Therefore, the attention-deficit hyperactivity disorder segment is expected to witness significant growth over the forecast period due to the abovementioned factors, including the rising prevalence of attention-deficit hyperactivity disorder.

North America is Expected to Witness Significant Growth Over the Forecast Period

• North America is expected to experience significant growth in the central nervous system (CNS) stimulant drugs market throughout the forecast period.
• The development of the central nervous system (CNS) stimulant drugs market is driven by the high healthcare expenditure, high prevalence of central nervous system diseases, expanding geriatric population, and presence of leading market players in the region. For instance, as per the data published by the Centre for ADHD Awareness, Canada (CADDAC) in 2023, ADHD is one of Canada's most common neurodevelopmental disorders, affecting over 1.8 million Canadians. Several clinical trials are ongoing in North America, especially in the United States. More than half of the total neurological disease clinical studies conducted worldwide are in the United States.
• Also, in March 2021, United States President Biden signed the American Rescue Plan Act 2021. According to the act, a portion of spending is allotted to mental health services, further increasing the government's activities toward neurological diseases. The rising disease burden, healthcare infrastructure, and supportive government initiatives make North America attractive for industries.
• Furthermore, according to a research study published in the British Medical Journal in 2021, approximately 4.1 million United States adults reported prescriptions for CNS stimulant drugs. The same source reported that the growth rate of the total number of prescriptions dispensed was about 96%, and significant percentage increases occurred in adults aged 25 years and older.
• Therefore, owing to the factors above, the growth of the studied market is anticipated in the North American region.

Central Nervous System (CNS) Stimulant Drugs Industry Overview

The central nervous system (CNS) stimulant drugs market is moderately competitive in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of some international as well as local companies that hold market shares and are well known, including Ironshore Pharmaceuticals Inc., Novartis AG, Takeda Pharmaceutical Co. Ltd, Azurity Pharmaceuticals, Inc., and Noven Therapeutics, LLC. Independence Pharmaceuticals, Janssen Pharmaceuticals, Inc., Elite Pharmaceuticals Inc., Kempharm, Inc., and Adlon Therapeutics L.P, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support